Terns Pharmaceuticals (TERN) Competitors $3.90 -0.10 (-2.50%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.90 0.00 (0.00%) As of 06/20/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TERN vs. JANX, VERA, ANIP, OCUL, BGM, TVTX, CVAC, AMPH, CALT, and GPCRShould you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Janux Therapeutics (JANX), Vera Therapeutics (VERA), ANI Pharmaceuticals (ANIP), Ocular Therapeutix (OCUL), Qilian International Holding Group (BGM), Travere Therapeutics (TVTX), CureVac (CVAC), Amphastar Pharmaceuticals (AMPH), Calliditas Therapeutics AB (publ) (CALT), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Terns Pharmaceuticals vs. Its Competitors Janux Therapeutics Vera Therapeutics ANI Pharmaceuticals Ocular Therapeutix Qilian International Holding Group Travere Therapeutics CureVac Amphastar Pharmaceuticals Calliditas Therapeutics AB (publ) Structure Therapeutics Terns Pharmaceuticals (NASDAQ:TERN) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings. Do institutionals and insiders believe in TERN or JANX? 98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to TERN or JANX? In the previous week, Terns Pharmaceuticals had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Terns Pharmaceuticals and 4 mentions for Janux Therapeutics. Terns Pharmaceuticals' average media sentiment score of 1.25 beat Janux Therapeutics' score of 0.91 indicating that Terns Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, TERN or JANX? Janux Therapeutics has higher revenue and earnings than Terns Pharmaceuticals. Janux Therapeutics is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$88.85M-$1.09-3.58Janux Therapeutics$10.59M131.86-$68.99M-$1.36-17.35 Which has more risk & volatility, TERN or JANX? Terns Pharmaceuticals has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.97, meaning that its stock price is 197% more volatile than the S&P 500. Do analysts rate TERN or JANX? Terns Pharmaceuticals presently has a consensus price target of $15.63, indicating a potential upside of 300.64%. Janux Therapeutics has a consensus price target of $95.25, indicating a potential upside of 303.60%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.09 Is TERN or JANX more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -9.29% beat Terns Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -28.81% -27.55% Janux Therapeutics -463.91%-9.29%-8.89% Does the MarketBeat Community believe in TERN or JANX? Terns Pharmaceuticals and Janux Therapeutics both received 44 outperform votes by MarketBeat users. However, 69.84% of users gave Janux Therapeutics an outperform vote while only 59.46% of users gave Terns Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTerns PharmaceuticalsOutperform Votes4459.46% Underperform Votes3040.54% Janux TherapeuticsOutperform Votes4469.84% Underperform Votes1930.16% SummaryJanux Therapeutics beats Terns Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TERN vs. The Competition Export to ExcelMetricTerns PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$340.63M$2.82B$5.18B$8.55BDividend YieldN/A2.69%5.38%4.21%P/E Ratio-3.5820.9225.7219.15Price / SalesN/A302.70414.02109.91Price / CashN/A40.9225.4426.73Price / Book0.967.427.925.78Net Income-$88.85M-$55.10M$3.15B$248.44M7 Day Performance-2.74%-2.51%-0.66%-0.29%1 Month Performance29.14%6.09%4.55%3.92%1 Year Performance-46.06%-1.66%41.89%15.59% Terns Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TERNTerns Pharmaceuticals4.3988 of 5 stars$3.90-2.5%$15.63+300.6%-46.1%$340.63MN/A-3.5840Positive NewsJANXJanux Therapeutics2.7184 of 5 stars$23.61-5.2%$95.25+303.4%-42.4%$1.40B$9.34M-20.1830VERAVera Therapeutics2.6036 of 5 stars$21.85-3.9%$65.00+197.5%-41.9%$1.39BN/A-8.3740Short Interest ↑ANIPANI Pharmaceuticals3.5888 of 5 stars$64.29+2.8%$80.13+24.6%+12.0%$1.39B$674.07M-116.89600Positive NewsOCULOcular Therapeutix3.542 of 5 stars$8.75+0.2%$16.25+85.7%+30.1%$1.39B$59.65M-6.63230Positive NewsBGMQilian International Holding GroupN/A$14.10+4.4%N/AN/A$1.37B$25.10M0.00298Gap UpHigh Trading VolumeTVTXTravere Therapeutics2.5054 of 5 stars$14.68+1.2%$32.14+119.0%+95.8%$1.30B$273.53M-3.58460CVACCureVac4.5362 of 5 stars$5.52-0.9%$9.00+63.0%+66.9%$1.24B$523.70M10.04880AMPHAmphastar Pharmaceuticals4.2119 of 5 stars$25.98+0.6%$32.33+24.5%-39.3%$1.22B$730.66M8.661,620Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics1.6616 of 5 stars$20.57-5.1%$76.50+271.9%-52.3%$1.18BN/A-27.80136 Related Companies and Tools Related Companies Janux Therapeutics Competitors Vera Therapeutics Competitors ANI Pharmaceuticals Competitors Ocular Therapeutix Competitors Qilian International Holding Group Competitors Travere Therapeutics Competitors CureVac Competitors Amphastar Pharmaceuticals Competitors Calliditas Therapeutics AB (publ) Competitors Structure Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TERN) was last updated on 6/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
